| Date Filed | Type | Description |
| 06/13/2023 |
SC 13G
| Schindel Yair Chaim reports a 6% stake in Akoya Biosciences, Inc. |
| 05/18/2023 |
SC 13D/A
| Schindel Yair Chaim reports a 7.7% stake in SOPHiA GENETICS SA |
| 01/30/2023 |
SC 13G
| Schindel Yair Chaim reports a 12.2% stake in Ayala Pharmaceutics, Inc |
| 01/23/2023 |
SC 13G/A
| Schindel Yair Chaim reports a 0% stake in Ayala Pharmaceutics, Inc |
| 01/10/2023 |
SC 13D/A
| Schindel Yair Chaim reports a 19.4% stake in Viracta Therapeutics, Inc. |
| 01/10/2023 |
SC 13D/A
| Schindel Yair Chaim reports a 19.4% stake in Viracta Therapeutics, Inc. |
| 01/10/2023 |
SC 13D
| Schindel Yair Chaim reports a 5% stake in SOPHiA GENETICS SA |
| 01/09/2023 |
SC 13G/A
| Schindel Yair Chaim reports a 20.2% stake in Ayala Pharmaceutics, Inc |
| 01/09/2023 |
SC 13G/A
| Schindel Yair Chaim reports a 6.2% stake in Sera Prognostics, Inc. |
| 01/09/2023 |
SC 13G/A
| Schindel Yair Chaim reports a 7.9% stake in Seer, Inc. |
| 01/24/2022 |
SC 13G
| Schindel Yair Chaim reports a 6.2% stake in Sera Prognostics, Inc. |
| 01/24/2022 |
SC 13G/A
| Schindel Yair Chaim reports a 21.5% stake in Ayala Pharmaceutics, Inc. |
| 01/24/2022 |
SC 13G/A
| Schindel Yair Chaim reports a 8% stake in Seer, Inc. |
| 03/02/2021 |
SC 13D
| Form SC 13D - General statement of acquisition of beneficial ownership: |
| 03/01/2021 |
SC 13D
| Form SC 13D - General statement of acquisition of beneficial ownership: |
| 02/18/2021 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
| 02/08/2021 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals: |
| 02/08/2021 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals: |
| 12/03/2020 |
SC 13D/A
| Schindel Yair Chaim reports a 5.6% stake in Adicet Bio, Inc. |
| 09/24/2020 |
SC 13D
| Schindel Yair Chaim reports a 5.8% stake in Adicet Bio, Inc. |